Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

s trial will be presented by the lead investigator, Prof. Peter Stalmans, at the Euretina Conference on May 23, in Vienna. The third and fourth cohorts from this trial will be presented at major ophthalmic conferences in the second half of 2008.

- Results are expected from the Phase II MITI IV trial in mid 2008.

This Phase II trial is evaluating the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. Once these data from the study have been reviewed, a decision will be made on the future development plans for microplasmin in the treatment of acute stroke.

It is ThromboGenics' current intention that it will only move forward with the development of microplasmin for the treatment of stroke in conjunction with a partner. This intention is based on both the risks and cost associated with the development of new stroke therapies and the Company's desire to invest in its other attractive pipeline product candidates, such as microplasmin in the treatment of back of the eye diseases and TB-403.

TB-403

- Results from the initial Phase I trial of this novel anti-cancer agent in healthy volunteers are expected in the third quarter of 2008.

Following the successful completion of this initial Phase I study, ThromboGenics expects to begin a Phase Ib trial with TB-403 in end stage cancer patients in mid 2008. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients and some early efficacy data on the product.

TB-402

- Top line results of the interaction studies to be announced by mid-2008.

TB-402 is being developed as an anti-coagulant for the prevention of deep vein thrombosis (DVT) after orthopaedic surgery and prevention of venous emboli in patients with atrial fibrillation. It is a novel human antibody that partially blocks Factor VIII, an essential blood clotting factor. The implicat
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... 19, 2014 Research and Markets ... the "Technology Innovations in Smart Fabrics (Technical ... http://photos.prnewswire.com/prnh/20130307/600769 The ... offers a detailed assessment on technological advancements and ... 1. The Smart Fabrics market ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... jobs Berbee ranks highly in Microsoft partner program ... Wausau police nab suspected wireless hacker ... parent company of SBC Wisconsin, will cut about 10,000 jobs by the ... According to spokesperson Howard Riefs, SBC does not know how many of ...
... we took a look at the PricewaterhouseCoopers quarterly report on venture ... As part of this analysis, we look at VC activity in ... region. , ,This week, lets take a look at VC ... any trends over time. Ready? Here we go! , , ...
... Trying to guess Tommy Thompsons next career move is like attempting ... see through the glass and make an educated guess but ... important disclaimer aside, here are some long-shot predictions about what Wisconsins ... of the U.S. Department of Health and Human Services. For those ...
Cached Biology Technology:Tech Digest: whats moving in the Midwest (11/8/04) 2Though VC investing is down, reloading on new funds is rising 2Though VC investing is down, reloading on new funds is rising 3Could Tommy Thompsons next stop be Transportation, Homeland Security, or the private sector? 2Could Tommy Thompsons next stop be Transportation, Homeland Security, or the private sector? 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... in the park can dramatically change natural ecosystems, according ... University of California, Berkeley. These findings could have important ... parks in the San Francisco Bay Area that allow ... with nearby nature reserves that allow no public access. ...
... Memorial Hospital of Chicago announced today that it has ... its Adult Phenylketonuria (PKU) Outreach Education Project. The ... PKU patients who are no longer being treated at ... education about recent developments in the management and treatment ...
... Researchers from four leading cancer centers have confirmed that ... to predict which lung cancer patients will have the worst ... that would help determine who needs more aggressive treatment. ... Nature Medicine . The researchers looked at ...
Cached Biology News:Outdoor enthusiasts scaring off native carnivores in parks 2Outdoor enthusiasts scaring off native carnivores in parks 3Outdoor enthusiasts scaring off native carnivores in parks 4Children's Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach 2Gene panel predicts lung cancer survival, study finds 2
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
... Competitor Assay Kits are ideal for studying ... PolarScreen GR Competitor Assay Kits contain partially ... one of the following proprietary fluorescent glucocorticoid ... Red (red assay kit), or GS Far ...
... to PRMT5 Arginine methylation is an ... recently been linked to protein activity. At ... been identified in mammalian cells. These enzymes ... functions by methylation of key proteins in ...
... coli Biotinylation Kit, Plasmid is designed for use ... expression kits. (Cat. No. 3 186 148, 3 ... vectors for the easy introduction of a C- ... can be enzymatically mono-biotinylated by E. coli biotin ...
Biology Products: